Management of paroxysmal nocturnal hemoglobinuria in CALR mutated post-essential thrombocythemia myelofibrosis: A case report
buff.ly/3UbndjJ

We will present the first comprehensive study comparing different ruxolitinib strategies in myelofibrosis undergoing transplant as oral at #EHA2024 European Hematology Association by Kristin Rathje #mpnsm

See you in Madri❤️🇪🇸 YoungEHA

At the upcoming #ASCO24 annual meeting, we’re presenting new efficacy and safety data from our Phase 3 MANIFEST-2 trial evaluating our investigational BET inhibitor in combination with a JAK inhibitor in #myelofibrosis . Learn more: bit.ly/3U9VujH

New endpoints in #myelofibrosis ‼️
A provocative 👀 topic by Naveen Pemmaraju, MD at the #MPN #MDS meeting #leusm

Interesting interview below w/ Bristol Myers Squibb CEO. One of the areas where they are decreasing investment: 'one asset we are deprioritizing is a BET inhibitor, 986158. It was a product we were developing in myelofibrosis and frankly, as we look at it, it simply didn’t meet…

We are going to Houston! See you there on May 9th
📍Houston, TX: buff.ly/4d0puHf

Krina Patel MD Anderson Cancer Center

#healthtree #bloodcancers #leukemia #lymphoma #myeloma #multiplemyeloma #smolderingmyeloma #mgus #cll #mds #aml #myelofibrosis #follicularlymphoma #dlbcl

John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai & The Tisch Cancer Institute Raajit Rampal, M.D.Ph.D., MD, PhD, of @sloan_kettering, & Michael Savona, MD, of VUMC Department of Medicine discuss disease progression, symptoms, and outcomes in patients with #myelofibrosis .
expertperspectives.com/disease-progre…

We are very proud of Lisa, Nurse Specialist, in completing her silver QI on frailty assessment in patients with Myelofibrosis. Absolutely delighted to hear that she won an award for best QI project in a very strong group. Fantastic effort! 👏👏

If you would like to help amore with her rare bone marrow cancer (myelofibrosis) journey, please consider donating.

All proceeds go to her to help with her day to day needs. We appreciate any help. It is a difficult situation.

All information on the foundation is on the…

John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai & The Tisch Cancer Institute Raajit Rampal, M.D.Ph.D., MD, PhD, of @sloan_kettering, & Michael Savona, MD, of VUMC Department of Medicine discuss disease progression, symptoms, and outcomes in patients with #myelofibrosis .
expertperspectives.com/disease-progre…

When the #ManOfTheDay #Co -Chair of MPN-MDS US focus meeting MD Education hits the stage !! The one and only Prithviraj Bose can publish and decipher this figure 😊 #MPNsm awesome session, #novel agents made easy #Myelofibrosis

📌 Mutations in Hematology

𝐉𝐀𝐊𝟐 𝐌𝐮𝐭𝐚𝐭𝐢𝐨𝐧
- Idiopathic Myelofibrosis
- Essential Thrombocythemia
- Polycythemia Vera

𝐁𝐂𝐑/𝐀𝐁𝐋 𝐌𝐮𝐭𝐚𝐭𝐢𝐨𝐧𝐬
- CML

𝐏𝐈𝐆𝐀 𝐠𝐞𝐧𝐞 𝐦𝐮𝐭𝐚𝐭𝐢𝐨𝐧
- Paroxysmal Nocturnal Hemoglobinuria

#CLUEmydiaHEMA

Proud to introduce this new WebMD series. A patient guide can make the MF experience easier to navigate, and anxiety of ET/PV progression. Questions for Your Doctor About Myelofibrosis MPN Research Foundation Canadian Mpn Research Foundation Silver MPN Center MPNAdvocatesNetwork PV Reporter #mpnsm webmd.com/apptprep/your-…

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting $KPTI healthstockshub.com/news/nasdaq/kp…

👏🏻 👏🏻 Largest contemporary analysis to date focussed on outcomes from MMRD allo-HCT in Myelofibrosis from our working party! The EBMT #MPNsm

In this podcast, Dr. Gaby Hobbs discusses updates in research, the role of emerging #myelofibrosis therapies, and shares advice for accessing quality care. Link in bio #mpnsm #MF

In our #ClinicalTrialClub webinar, J.J. Kiladjian and Angela Fleischman, discussed treatment sequencing for anemic #myelofibrosis .

Watch their presentations and the Q&A session below!

loom.ly/fPAcWZQ
loom.ly/1r04zq8
loom.ly/mNUMiDA

#MPN #MPN sm Angela Fleischman

This episode of Oncology Today with Dr Neil Love features an interview with Dr Naveen Pemmaraju about updated findings from ASH 2023 on the management of myelofibrosis, polycythemia vera and essential thrombocythemia.

bit.ly/44n82cc

Dr Ruben Mesa Ruben A. Mesa, MD giving an outstanding talk on JAK inhibitors for myelofibrosis #MFsm joined by panelist Dr Nikolai Podoltsev Yale Cancer Center who also summarized all prognostic scores with excellent moderatation by Dr Prithviraj Bose at MD Education #MDSsm & #MPNsm meeting

MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting $MOR healthstockshub.com/news/nasdaq/mo…